GlassScriptPhysician profile
Alexander T Harrison
NPI 1396934188
$13,604.38
in general payments reported to CMS, 2019-2025
37 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,701 · 2020: $747 · 2021: $982 · 2022: $1,370 · 2023: $2,048 · 2024: $2,945 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,657 · Travel and Lodging: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,656.82 |
| Travel and Lodging | $1,147.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,536.12 | 2019-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Assurity |
| Amgen INC. | $1,458.42 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $1,308.88 | 2019-2025 | Watchman Access System, Emblem Mri S-Icd, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $774.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $673.13 | 2021-2025 | Verquvo, Winrevair |
| Astrazeneca Pharmaceuticals LP | $613.98 | 2019-2025 | Farxiga, Andexxa, Wainua |
| Esperion Therapeutics, INC. | $480.51 | 2020-2025 | Nexletol, Nexlizet |
| E.R. Squibb & Sons, L.L.C. | $455.66 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.38 | 2019-2025 | Jardiance |
| Medtronic, INC. | $321.71 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Janssen Pharmaceuticals, INC | $279.92 | 2019-2024 | Xarelto |
| Pfizer INC. | $263.70 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $260.75 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $243.95 | 2019-2023 | |
| Heartflow, INC. | $175.13 | 2019-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.